ClinicalTrials.gg
Not yet recruitingNCT07704944Updated Jul 15, 2026

Safety and Dose-Response of Bletilla Formosana in Prediabetic Subjects

A Phase 1/2 interventional study of Bletilla formosana (BF) powder and Placebo in Prediabetes, sponsored by Chang Gung Memorial Hospital. Not yet recruiting at 3 sites in Taiwan. Open to participants aged 30 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Chang Gung Memorial Hospital · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
30 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Prediabetic State with a site in Taiwan — 4 open to participants now, 6 under way, 1 of them phase 3. Prediabetic State · Taiwan.

Planned enrollment
9th of 12
94 · median 151
Started
2026
with 2 others
Phase 1/2
Only one
of the 15
Registered
14th of 15
by date
Lead sponsor
2 of 15
Chang Gung Memorial Hospital

Among the 15 studies in Prediabetic State with a site in Taiwan, this one is the 9th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2026, is the only one in phase 1/2, and was the 14th registered.

Prediabetic State

919 studies on the registry are indexed under Prediabetic State; 231 are open to participants now.

Browse Prediabetic State studies →

Open to participants now

4 of the 15 studies in Prediabetic State with a site in Taiwan are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 144 Prediabetic State studies recruiting now, 51 (35%) set no upper age limit and 83 (58%) stop at 75 or younger; 12 take children under 18; 54 take healthy volunteers.

This study: 30 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Prediabetic State with a site in Taiwan, or all of them as a file.
02

Study summary

This study evaluates the safety and preliminary efficacy of Bletilla formosana (BF), a traditional herbal medicine, in adults with prediabetes. Prediabetes is a high-risk condition where blood sugar levels are elevated, often leading to type 2 diabetes. While lifestyle changes are the standard treatment, researchers are exploring herbal supplements as a complementary way to support metabolic health. Preclinical research has shown that BF possesses anti-inflammatory properties and may help regulate blood glucose. Participants in this study will be randomly assigned to receive either a high dose of BF, a low dose of BF, or a placebo (an inactive substance) for 12 weeks. The total study duration is approximately 24 weeks, involving four clinic visits for blood tests and safety monitoring to see how BF affects blood sugar markers and inflammation.

Read the detailed description

This is a single-center, Phase I/II, randomized, double-blind, placebo-controlled, parallel-design trial. The primary goal is to translate robust preclinical findings-where BF extract was shown to inhibit neutrophil-driven inflammation and improve glycemic parameters in animal models-into clinical evidence.

A total of 94 prediabetic subjects (defined by FPG 100-125 mg/dL or HbA1c 5.7%-6.4%) will be enrolled.

Participants will be randomized in a 2:2:1 ratio into one of the following three arms:

High-dose group: 3g Bletilla formosana powder daily. Low-dose group: 1.5g Bletilla formosana powder plus 1.5g placebo daily. Placebo group: 3g inactive placebo powder daily.

The study consists of three distinct phases:

Screening Phase: Up to 2 weeks for eligibility confirmation. Treatment Phase: 12 weeks of oral administration. Follow-up Phase: 12 weeks post-treatment to evaluate sustained efficacy and safety outcomes.

Phase I objectives focus on safety and tolerability, with adverse events (AEs) and serious adverse events (SAEs) graded according to CTCAE v5.0.

Phase II objectives explore preliminary efficacy through changes in fasting plasma glucose (FPG), HbA1c, and HOMA-IR.

Secondary endpoints include assessment of inflammatory biomarkers (TNF-α, IL-6, and CRP) and lipid profiles.

Clinical assessments, including 12-lead ECG and comprehensive laboratory testing, are scheduled at Screening, Week 6, Week 12 (end of treatment), and Week 24 (end of study).

03

Conditions studied

  • Prediabetes

Browse trials for

Keywords

  • Prediabetes
  • Bletilla formosana
  • Traditional Chinese Medicine
  • Herbal Medicine
  • Glycemic Control
  • Anti-inflammatory
  • Dose-Response Relationship
  • Phase I/II Trial
  • Randomized Controlled Trial
  • Safety and Tolerability
04

Who can participate

Ages eligible
30 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged 30-70 years.
  2. Prediabetes defined by any of the following:
  3. Fasting Plasma Glucose (FPG) of 100-125 mg/dL, or
  4. (HbA1c) of 5.7%-6.4%.
  5. Willingness to provide written and comply with study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Established type 1 or type 2 diabetes mellitus, or recent use of oral antidiabetic agents or insulin (within 3 months).
  2. Abnormal liver function, defined as (ALT) or Aspartate aminotransferase (AST) exceeding 2-fold the upper reference limit (≥2 × ) at screening.
  3. Abnormal renal function, defined as serum creatinine (Cr) >1.5 mg/dL or Estimated (eGFR) \<60 mL/min/1.73 m².
  4. Gastrointestinal disorders that may affect drug absorption, such as gastrostomy, enterostomy, severe chronic diarrhea, or malabsorption syndrome.
  5. Severe comorbidities within the past 6 months, including major stroke, myocardial infarction, major trauma, or major surgery.
  6. Recent use of medications (within 1 month) that may significantly alter blood glucose or lipids, such as systemic or non-stable doses of lipid-lowering agents.
  7. Malignant tumor under active treatment, or immunodeficiency/ disorders requiring therapy.
  8. Psychiatric disorders or cognitive impairment that may affect protocol compliance.
  9. Active use of other drugs within 3 months prior to screening.
  10. Pregnancy or lactation.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
94 participants (estimated)

Study arms

  • Experimental
    High-dose Bletilla formosana (BF)

    Participants receive 3g of Bletilla formosana powder daily for 12 weeks. To maintain blinding, the total dose is divided into two 1.5g sachets (one in the morning and one in the evening).

    Drug: Bletilla formosana (BF) powder

  • Experimental
    Low-dose Bletilla formosana (BF)

    Participants receive 1.5g of Bletilla formosana powder and 1.5g of placebo powder daily for 12 weeks. To maintain blinding, this is administered as one active sachet and one matching placebo sachet (one in the morning and one in the evening).

    Drug: Bletilla formosana (BF) powder · Other: Placebo

  • Placebo comparator
    Placebo

    Participants receive 3g of inactive placebo powder daily for 12 weeks. To maintain blinding, this is administered as two matching placebo sachets (one in the morning and one in the evening).

    Other: Placebo

Interventions

  • DrugBletilla formosana (BF) powder

    A traditional Chinese medicinal herb (Taiwanese ground orchid). The raw material is derived from the approved botanical species and medicinal part listed in the Taiwan Herbal Pharmacopoeia.

  • OtherPlacebo

    An inactive powder matching the appearance and dosage form of the BF powder, consisting of starch and caramel coloring.

06

What researchers measure

Primary outcomes

  1. Number of Participants with at Least One Treatment-Emergent Adverse Event (AE)

    Incidence of all adverse events (AEs) graded by CTCAE v5.0.

    Time frame: From baseline to Week 24.

  2. Number of Participants with Serious Adverse Events (SAEs)

    Number of participants experiencing life-threatening or fatal events according to ICH-GCP definitions.

    Time frame: From baseline to Week 24

  3. Change from Baseline in Fasting Plasma Glucose (FPG) (mg/dL)

    Change in fasting blood sugar levels to assess the preliminary glycemic efficacy of Bletilla formosana.

    Time frame: Baseline, Week 6, Week 12, and Week 24.

  4. Change from Baseline in Glycated Hemoglobin (HbA1c) (%)

    Assessment of average blood glucose control over time.

    Time frame: Baseline, Week 6, Week 12, and Week 24.

  5. Change from Baseline in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)

    Calculated using fasting insulin and glucose levels to assess changes in insulin sensitivity.

    Time frame: Baseline, Week 6, Week 12, and Week 24.

Secondary outcomes

  1. Change from Baseline in Tumor Necrosis Factor-alpha (TNF-α) (pg/mL)

    To evaluate the anti-inflammatory effects of Bletilla formosana.

    Time frame: Baseline, Week 6, Week 12, and Week 24.

  2. Change from Baseline in Interleukin-6 (IL-6) (pg/mL)

    To evaluate the anti-inflammatory effects of Bletilla formosana.

    Time frame: Baseline, Week 6, Week 12, and Week 24.

  3. Change from Baseline in C-reactive protein (CRP) (mg/dL)

    To evaluate the anti-inflammatory effects of Bletilla formosana.

    Time frame: Baseline, Week 6, Week 12, and Week 24.

  4. Change from Baseline in Total Cholesterol (mg/dL)

    Assessment of lipid profiles using standard laboratory methods

    Time frame: Baseline, Week 6, Week 12, and Week 24.

  5. Change from Baseline in High-Density Lipoprotein (HDL) (mg/dL)

    Assessment of lipid profiles using standard laboratory methods.

    Time frame: Baseline, Week 6, Week 12, and Week 24.

  6. Change from Baseline in Low-Density Lipoprotein (LDL) (mg/dL)

    Assessment of lipid profiles using standard laboratory methods.

    Time frame: Baseline, Week 6, Week 12, and Week 24.

  7. Change from Baseline in Triglycerides (TG) (mg/dL)

    Assessment of lipid profiles using standard laboratory methods.

    Time frame: Baseline, Week 6, Week 12, and Week 24.

Other outcomes

  1. Change from Baseline in Alanine Aminotransferase (ALT) (U/L)

    Assessment of clinical laboratory safety tests to monitor hepatic, renal, and hematologic function.

    Time frame: Baseline, Week 6, Week 12, and Week 24.

  2. Change from Baseline in Aspartate Aminotransferase (AST) (U/L)

    Assessment of clinical laboratory safety tests to monitor hepatic, renal, and hematologic function.

    Time frame: Baseline, Week 6, Week 12, and Week 24.

  3. Change from Baseline in Total Bilirubin (mg/dL)

    Assessment of clinical laboratory safety tests to monitor hepatic, renal, and hematologic function.

    Time frame: Baseline, Week 6, Week 12, and Week 24.

  4. Change from Baseline in Blood Urea Nitrogen (BUN) (mg/dL)

    Assessment of clinical laboratory safety tests to monitor hepatic, renal, and hematologic function.

    Time frame: Baseline, Week 6, Week 12, and Week 24.

  5. Change from Baseline in Serum Creatinine (mg/dL)

    Assessment of clinical laboratory safety tests to monitor hepatic, renal, and hematologic function.

    Time frame: Baseline, Week 6, Week 12, and Week 24.

  6. Change from Baseline in White Blood Cell Count (WBC) (10^3/μL)

    Assessment of clinical laboratory safety tests to monitor hepatic, renal, and hematologic function.

    Time frame: Baseline, Week 6, Week 12, and Week 24.

  7. Change from Baseline in Hemoglobin (Hb) (g/dL)

    Assessment of clinical laboratory safety tests to monitor hepatic, renal, and hematologic function.

    Time frame: Baseline, Week 6, Week 12, and Week 24.

  8. Change from Baseline in Platelet Count (10^3/μL)

    Assessment of clinical laboratory safety tests to monitor hepatic, renal, and hematologic function.

    Time frame: Baseline, Week 6, Week 12, and Week 24.

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: No — The study team does not have a plan to share individual participant data at this time to maintain participant confidentiality as stated in the informed consent.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2026; primary completion for Jul 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2026
First posted
Jul 15, 2026
StartEst.
Jul 1, 2026
Primary completionEst.
Jul 1, 2027
CompletionEst.
Aug 1, 2027
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07704944
Collaborators
National Science and Technology Council
Responsible party
YUAN-CHIEH YEH (Associate Professor / Attending Physician, Chang Gung Memorial Hospital) — Principal investigator
First posted
Jul 15, 2026
Start date
Jul 1, 2026 (estimated)
Primary completion
Jul 1, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Jul 15, 2026

Study contacts

Yuan-Chieh Yeh, MD
Contact
b9005030@cgmh.org.tw
+886-2-24313131 ext. 6320
Yu-Chieh Peng, Bachelor
Contact
sunnypon1013@gmail.com
+886-2-2431-2540
Yuan-Chieh Yeh, MD
principal investigator · Chang Gung Memorial Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion